BioCentury
ARTICLE | Clinical News

Shire reports Phase III dry eye data for lifitegrast

December 6, 2013 1:54 AM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) reported data on Thursday from the 718-patient Phase III OPUS-2 trial evaluating twice-daily 5% lifitegrast ( SAR 1118) to treat dry eye disease. Lifitegrast met the co-primary endpoint of improving patient-reported eye dryness scores from baseline to week 12 vs. placebo (p<0.0001), but missed the co-primary endpoint of improving inferior corneal staining scores from baseline to week 12 vs. placebo (p=0.6186).

Shire gained lifitegrast -- an eye drop formulation of a small molecule integrin beta(2) (LFA-1; MAC-1; CD18) antagonist -- through its April acquisition of SARcode Bioscience Inc. (see BioCentury, April 1). ...